Nexiritide is a synthetic human brain natriuretic peptide (BNChemicalbookP) obtained from Escherichiacoli using recombinant DNA technology, and its effect is very similar to that of human BNP. It contains a 32-amino acid polypeptide linked by a disulfide bond between its l0th and 26th amino acids (both cysteine) to form a l7-amino acid ring. Nesiritide acts after binding to natriuretic peptide type A receptor and type B receptor. In addition to increasing cGMP production, nesirinotide can also reduce renin-angiotensin system (RAS) and sympathetic nerve activity; It has a definite dilating effect on arterioles and venules throughout the body; It can significantly reduce pulmonary capillary intercalation pressure and right atrial pressure J, and reduce cardiac preload in heart failure. Neciritide also significantly reduces total peripheral vascular resistance, thereby reducing cardiac afterload in heart failure; has the effect of increasing cardiac index, the mechanism of which is related to the reduction of cardiac afterload; It has a specific dilating effect on coronary arteries; It also has the effect of reducing myocardial oxygen consumption.